Stocks › BBTX

Bambusa Therapeutics, Inc.

BBTX·Nasdaq·United States United States·USD
$16.00
+0.45 (+2.89%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BBTX
Bambusa Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BBTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of BBTX by members of U.S. Congress · 0 on record

No congressional trades in BBTX on record.

Whale Activity

Institutional 13F positions

No 13F filer has reported a position in BBTX for a completed quarter.

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by BBTX insiders, by quarter · Form 4
-5.0M-2.5M02.5M5.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 3.3M2026 Q4

Recent Insider Transactions

6 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Kolchinsky Peter / Shah Rajeev M.Director · Director Purchase +2.3M n/c — Nov 2, 2026 Form 4 ↗
RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Kolchinsky Peter / Shah Rajeev M.Director · Director Purchase +164.9K $16.00 $2.6M Nov 2, 2026 Form 4 ↗
Salvia Investment GmbH Purchase +375.0K $16.00 $6.0M Nov 2, 2026 Form 4 ↗
RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Kolchinsky Peter / Shah Rajeev M.Director · Director Purchase +263.9K $14.92 $3.9M Oct 30, 2026 Form 4 ↗
RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Kolchinsky Peter / Shah Rajeev M.Director · Director Purchase +189.9K $14.23 $2.7M Oct 30, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding BBTX · SEC Form N-PORT

Funds report their holdings by CUSIP, and BBTX could not be matched to one, so no fund holdings are shown.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • RA Capital Healthcare Fund, L.P.SCHEDULE 13D · activist (13D) · 5.9M shares11.6%
    Nov 6, 2026 · ↗
  • Rajeev ShahSCHEDULE 13D · activist (13D) · 7.4M shares14.6%
    Nov 6, 2026 · ↗
  • Peter KolchinskySCHEDULE 13D · activist (13D) · 7.4M shares14.6%
    Nov 6, 2026 · ↗
  • RA Capital Management, L.P.SCHEDULE 13D · activist (13D) · 7.4M shares14.6%
    Nov 6, 2026 · ↗
  • Thomas MaierSCHEDULE 13G · passive (13G) · 4.7M shares9.2%
    Nov 5, 2026 · ↗
  • Salzufer Holding Inc.SCHEDULE 13G · passive (13G) · 4.6M shares9.0%
    Nov 5, 2026 · ↗
  • Objektgesellschaft Salzufer 1 GmbHSCHEDULE 13G · passive (13G) · 4.6M shares9.0%
    Nov 5, 2026 · ↗
  • ATHOS KGSCHEDULE 13G · passive (13G) · 4.6M shares9.0%
    Nov 5, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Bambusa Therapeutics, Inc. as client

No lobbying filings found naming Bambusa Therapeutics, Inc. as the client.

Government Contracts

Federal awards to Bambusa Therapeutics, Inc. · USAspending

No federal contract awards found for Bambusa Therapeutics, Inc..

U.S. Patents

Recent USPTO applications naming Bambusa Therapeutics, Inc.

No USPTO patent applications found for Bambusa Therapeutics, Inc..

Annual Financials

From BBTX's 10-K filings · XBRL

SEC holds no annual XBRL figures in US dollars for Bambusa Therapeutics, Inc..

Stock Splits

Every split and reverse split in the price history

No stock splits in BBTX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 5.03, 7.01, 9.01Bylaw amendment · Reg FD disclosureNov 3, 2026
    EDGAR ↗

About Bambusa Therapeutics, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersBOSTON, MA
IncorporatedDE